Haematologica (Dec 2020)

Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis

  • Thomas Milan,
  • Magalie Celton,
  • Karine Lagacé,
  • Élodie Roques,
  • Safia Safa-Tahar-Henni,
  • Eva Bresson,
  • Anne Bergeron,
  • Josée Hebert,
  • Soheil Meshinchi,
  • Sonia Cellot,
  • Frédéric Barabé,
  • Brian T Wilhelm

DOI
https://doi.org/10.3324/haematol.2020.271619
Journal volume & issue
Vol. 107, no. 1

Abstract

Read online

Chromosomal translocations involving the KMT2A gene are among the most common genetic alterations found in pediatric acute myeloid leukemias although the molecular mechanisms that initiate the disease remain incompletely defined. To elucidate these initiating events we used a human model system of acute myeloid leukemia driven by the KMT2A-MLLT3 (KM3) fusion. More specifically, we investigated changes in DNA methylation, histone modifications, and chromatin accessibility at each stage of our model system and correlated these with expression changes. We observed the development of a pronounced hypomethyl - ation phenotype in the early stages of leukemic transformation after KM3 addition along with loss of expression of stem-cell-associated genes and skewed expression of other genes, such as S100A8/9, implicated in leukemogenesis. In addition, early increases in the expression of the lysine demethylase KDM4B was functionally linked to these expression changes as well as other key transcription factors. Remarkably, our ATAC-sequencing data showed that there were relatively few leukemia-specific changes and that the vast majority corresponded to open chromatin regions and transcription factor clusters previously observed in other cell types. Integration of the gene expression and epigenetic changes revealed that the adenylate cyclase gene ADCY9 is an essential gene in KM3-acute myeloid leukemia, and suggested the potential for autocrine signaling through the chemokine receptor CCR1 and CCL23 ligand. Collectively, our results suggest that KM3 induces subtle changes in the epigenome while co-opting the normal transcriptional machinery to drive leukemogenesis.